

CURRICULUM VITAE

1. NAME: Amy L. Dunn M.D.
2. OFFICE ADDRESS: Nationwide Children's Hospital
700 Children's Way
Columbus, OH 43205
3. E-MAIL ADDRESS: amy.dunn@nationwidechildrens.org
4. CITIZENSHIP: US Citizen
5. CURRENT TITLES AND AFFILIATIONS:
 - a. Academic appointments:
 1. Primary Appointment:

Assistant Professor of Pediatrics,
Division of Pediatric Hematology/Oncology
Emory University/Children's Healthcare of Atlanta, 2000-2013

Associate Professor of Pediatrics,
Division of Pediatric Hematology/Oncology
Emory University/Children's Healthcare of Atlanta, 2013-Jan 2014

Adjunct Associate Professor of Pediatrics,
Division of Pediatric Hematology/Oncology
Emory University/Children's Healthcare of Atlanta, Jan 2014-present

Associate Professor of Pediatrics,
Division of Pediatric Hematology/Oncology
Ohio State University/Nationwide Children's Hospital, Jan 13, 2014
6. LICENSURES/BOARDS:

Georgia Issued: 1996
7. SPECIALTY BOARDS:

Board of Pediatrics – 1997, 2004, 2011, 2014

Board of Pediatric Hematology Oncology – 2000, 2007
8. EDUCATION:

1986-1990 B.A., Miami University

1990-1994 M.D. Wright State University School of Medicine

9. POSTGRADUATE TRAINING:

Pediatric Residency: Emory University School of Medicine, Atlanta, GA, D. Susie Buchter M.D. 1994-1997.

Pediatric Hematology-Oncology Fellowship: Emory University School of Medicine/Children's Healthcare of Atlanta, Atlanta, GA, Thomas C. Abshire M.D. 1997-2000.

10. COMMITTEE MEMBERSHIPS:

a. National and International:

International Prophylaxis Study Group: Expert Imaging Working Group, 2005-present.

National Heart Lung and Blood Institute Transfusion Medicine Network: Inherited Bleeding Disorders Subcommittee. Co-chair 2004-2007.

International Network on Pediatric Hemophilia. 2009-present.

Hemophilia and Thrombosis Research Society, 2004-present. Member of the Director Nominating Committee 2011, Mentored Research Award Review Committee, 2013.

DSMB member CSL Behring new therapeutic agents 2012-present.

Children's Hospital Association. 2012-2013

IDMC member Biogen IDEC new therapeutic agents 2014-present

National Hemophilia Foundation annual meeting abstract review panel 2014

American Thrombosis and Hemostasis Network-Quality Improvement Committee
2014-present

World Federation of Hemophilia USA Board-2014-present

b. Regional and State:

Georgia State Hemophilia Medical Advisory Board. 2004-2013.

Camp Wannaklot, a summer camp for children with bleeding disorders. Camp Physician 1997-2013, Medical Director. 2008-2013.

Grant review committee Pfizer Aspire Hemophilia Awards, 2012-present
Central Ohio Hemophilia Chapter Advisory Board-2014-present
Hemophilia Treatment Centers Network for the CDC/NCBDDD Division of Blood
Presentation & Publication Committee-2014-present
Great Lakes Hemophilia Treatment Center Network Regional Planning
Committee 2014
Great Lakes Hemophilia Treatment Center Network- Regional Advisory Council
2014
World Federation of Hemophilia USA Board-2014

b. Institutional:

Aflac Blood Stream Infection Committee 2011-2013.
Aflac Epidemiology Faculty Recruitment committee 2012-2013.
Nationwide Children's Hospital Service Line Director committee 2014-present
Nationwide Children's Hospital Mentorship Design Group 2014
Nationwide Children's Hospital Pharmacoeconomic Committee 2015

11. **Consultantships/Advisory Boards**

CSL Behring, Advisor, 2005-present.
Von Willebrand Leadership advisory board, 2005-present.
Global Advisory board, 2007-present.
Hemophilia Management advisory board, 2007-present.
Factor VIII single chain-DSMB member, 2012-present.
Factor IX single chain-DSMB member 2013-present.

Bayer Healthcare, Hemophilia Advisory Board member, 2005-present, Co-Chair,
2012-present.

Baxter Healthcare, Investigator, 2006-present.

Ferring Research Institute, Consultant, 2006.

Kedrion-Hemophilia Advisory board member, 2012.

Biogen Idec, Hemophilia Advisory board member, 2011-present
Factor IX-Fc-DSMB member 2014-present
Factor VIII-Fc-DSMB member 2014-present

Pfizer, Advisory Board member, 2013-present

12. Editorships and Editorial Boards:

HemAware. 2007-present-Assistant Editor.

I-Lights Hemophilia 2011-2012-Editor in Chief.

13. Manuscript Reviewer:

Haemophilia. 2004-present.

American Journal of Hematology, 2006.

Pediatric Blood and Cancer, 2007-present.

Blood, 2010-present.

Journal of Pediatrics, 2011.

Osteoarthritis and Cartilage, 2012.

Journal of Thrombosis and Haemostasis, 2012-present.

14. Honors and Awards:

Atlanta Business Chronicle Healthcare Hero for Healthcare Innovation 2007.

US News and World Report Top Doctors 2013

Castle Connolly Regional Top Doctor 2014

15. Membership in Professional Societies:

Alliance of Five-Hemophilia Research Society, 2004-2010. Annual meeting chair 2010.

Hemophilia and Thrombosis Research Society, 2004-present. Member of the Director Nominating Committee 2011, Mentored Research Award Review Committee, 2013.

National Hemophilia Foundation, 2004-present.

International Society of Thrombosis and Haemostasis, 2005-present.

International Prophylaxis Study Group, 2005-present. Member of the Expert Imaging Working Group, 2005-present.

American Society of Hematology, 2008-present.

International Pediatric Hemophilia Network, 2009-present.

World Federation of Hemophilia, 2014-present

16. Organization of National/International Conferences:

Chair, Organizing Committee for the conference "Randomized treatment of early target joint bleeding in children with hemophilia", National Hemophilia Foundation Annual Meeting: Orlando FL. 2002.

Chair, Organizing Committee for the conference "Promoting collaborative clinical trials in patients with bleeding and clotting disorders" Alliance of 5 annual meeting, Atlanta, GA 2009.

Chair, Organizing Committee "Inhibitors to FVIII Translating the Bench to Bedside", Nationwide Children's Hospital Columbus, OH May 18, 2015.

17. Research Focus:

My clinical research focus is twofold, first to improve clinical care of patients with bleeding disorders and to investigate the phenotypic differences in bleeding patterns in patients with hemophilia.

18. Grant Support:

a. Active Support:

1. Federally Funded

Co-I., U54 HL112309-01, "*Biological Variation in Hemophilia*", 20% effort, June 2012-2017, total direct and indirect \$14,161,601.

2. Private foundation funded:

Co-I., Aflac PHORG'-3-Dimensional Gait Analysis in Children with Hemophilia. Investigator initiated-2013-present. Total direct and indirect \$50,000

P.I., Hemophilia Foundation of Michigan / Cascade Hemophilia Consortium, *Patient and Family Support Group for Hemophilia Clinic (Cascade)* 6/1/2014 – 5/31/2015. \$103,872

P.I., CDC 477312 Hemophilia Foundation of Michigan / Centers for Disease Control and Prevention *Public health surveillance for the prevention of complications of bleeding and clotting disorders.* 2/2013-present. \$14,000

P.I. American Thrombosis and Hemostasis Network / Biogen Idec MA, Inc.
My Life, Our Future: A Hemophilia Genotyping Initiative Data and Sample Research Repository, pending, \$2,389

P.I., American Thrombosis and Hemostasis Network. *Data Quality Counts*. 7/1/2014-6/30/2015. \$11,500.00

3. Contracts:

P.I., Biogen IDEC 998HB303Pups B . *Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention & Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B*. 2104-2016 Clinical Trial

P.I., Biogen IDEC 997HA306Pups A. *Open-Label, Multicenter Evaluation of the Safety & Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIII Fc; BIIB031) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia A* 2014-2016 Clinical Trial

P.I., Baxter Healthcare Corporation. *A Phase 3 prospective, uncontrolled, multicenter study evaluating pharmacokinetics, efficacy, safety, and immunogenicity of BAX 855 in previously treated pediatric patients with severe hemophilia A*. 2014-2016 Clinical Trial

Co-P.I., Indiana Hemophilia and Thrombosis Center. *Hemophilia Inhibitor Research Study Phase III Protocol*. 4/1/2014-9/30/2105

P.I., Novo Nordisk Independent Medical Education Activity Grant “Factor VIII Inhibitors: From Bench to Bedside,” 5/17-5/18/2015, \$9,207.03

P.I., Baxter Healthcare Independent Medical Education Grant “Factor VIII Inhibitors: From Bench to Bedside,” 5/17-5/18/2015, \$47,308.00

P.I., CSL Behring Independent Medical Education Grant “Factor VIII Inhibitors: From Bench to Bedside,” 5/17-5/18/2015, \$8,800.00

P.I., Bayer Independent Medical Education Grant “Factor VIII Inhibitors: From Bench to Bedside,” 5/17-5/18/2015, \$15,000.00.

P.I., Biogen Independent Medical Education Grant “Factor VIII Inhibitors: From Bench to Bedside,” 5/17-5/18/2015, \$20,000.00.

American Thrombosis and Hemostasis Network Radionuclide Synovectomy/Synoviorthesis (RS) In Patients with Bleeding Disorders: Pilot Processes 1/1/2015-12/31/2015, \$15,000.00.

b. Previous Support

1. Federally funded:

Co-P.I., NHLBI Transfusion Medicine/Hemostasis Research Network *The Safety/Efficacy of using Rituximab in the Eradication of Inhibitors to Factor VIII*. 2008-2010. Clinical Trial-completed.

Local P.I., NHLBI PO1 HL081588-01; *The Relative Molecular Impact of von Willebrand Disease (VWD) and low or Abnormal von Willebrand Factor (VWF) on Clinical Aspects of the Disease*. 2011-2013.

2. Private foundation funded:

P.I., Aventis Behring Foundation. *The Management of Hemophilic Early Target Joint Bleeding – a clinical trial of the use of synovectomy in patients with hemophilic joint disease*. 2002-2004.

P.I., New York Presbyterian Hospital. *Bleeding and treatment patterns in females with Moderate or Severe Hemophilia A or B*. 2005-2007. Clinical Trial Completed– Investigator initiated-completed.

P.I., Central Manchester Healthcare Trust, England. *International Trial of Immune Tolerance Induction Study - the safest and most efficacious treatment regimen for the eradication of inhibitors to Factor VIII replacement products through immune tolerance induction*. 2007-2009. Clinical Trial-completed. Investigator Initiated-completed.

P.I., Central Manchester Healthcare Trust, England. *Hemophilic Genotype, Inhibitors and Response to Immune Tolerance - the impact of factor VIII gene mutation analysis on success or failure of immune tolerance induction*. 2007-2011, Clinical Trial-completed. Investigator Initiated-completed.

P.I., New York Presbyterian Hospital., *Genotype Substudy in Females with Severe or moderate Hemophilia A or B - To determine factor mutations in females with hemophilia*. 2007-2010. Clinical Trial completed–Investigator initiated-completed.

P.I., Hemophilia of Georgia Clinical Scientist Development Grant. *Articular cartilage changes in a hemophilic mouse bleeding model*. 2005-2010.

P.I., Emory/Egleston Pediatric Research Center Seed Grant. *Pathobiologic Mechanisms of articular cartilage changes from blood induced joint disease in a hemophilic mouse model*. 2007-2008.

P.I., Goerlich Family Foundation unrestricted grant for hemophilia research. 2008-2009.

P.I., Emory/Egleston Pediatric Research Center Seed Grant to promote use of core facilities. *An M.R.I. model of murine blood induced joint disease*. 2008-2009.

Co-I., Rho, Inc. *von Willebrand Disease Prophylaxis Network (vWD PN) the VWD International Prophylaxis (VIP) - Determine the safety and efficacy of prophylaxis in vWD*. 2008-December 2012, Clinical Trial- Investigator initiated.

Co-P.I., Aflac PHORG grant. *Effect of genotype on phenotypic severity in patients with severe hemophilia*. 2010-2011. Clinical Trial-Investigator initiated-completed.

Co-I., Sepulveda Research Corporation/ VA of Greater LA Healthcare System *Go Grant-Mechanisms of raced based differences of factor VIII immunogenicity*. 2010-2012 Clinical Trial-completed.

P.I., University of Colorado. *Continuation of Children Enrolled in Protocol #95-011, A Randomized Prospective Study for the Prevention of Joint Disease in Children with Severe Factor VIII Deficiency*. 2011-2013, Clinical Trial-Investigator Initiated.

3. Contracts:

P.I., Baxter Healthcare Corporation. *Phase 3B Recombinant Antihemophilic factor manufactured and formulated without added human or animal proteins (rAHF PFM) - Evaluation of immunogenicity, efficacy and safety in previously untreated patients with hemophilia A*. 2004-2009. Clinical Trial-completed.

P.I., Wyeth. Retrospective BeneFIX Study. *Incidence of moderate to severe allergic reactions to factor IX in patients with hemophilia B*. 2005-2007. Clinical Trial –Clinical Trial-completed.

Co-P.I., CSL Behring. *Platelet Function and Severe Hemophilia - Investigate role of thrombin production and platelet activation in the clinical phenotype of patients with severe hemophilia*. 2009-December 2012. Clinical Trial-completed.

P.I., Baxter Healthcare Corporation. *A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2mL versus 5mL SWFI in Previously Treated Severe Hemophilia A Patients*. Clinical Trial-completed.

Co-I., ZLB Behring. *Administration of Factor XIII Concentrate, Fibrogammin P - Safety and Efficacy Study of Fibrogammin P in Factor XIII Deficiency* Clinical Trial-completed.

P.I., Biogen IDEC 9HB02PED, *An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein, BII029, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia B*, 2012-2013, Clinical Trial.

Co-I., Novo Nordisk 3720-Recombinant Factor XIII-*Determine the safety and efficacy of rFXIII in the treatment of individuals with factor XIII deficiency*. 2010-2013, Clinical Trial.

P.I.-Baxter 855 *Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)*, 2013, Clinical Trial.

Co-I., **Amgen Romiplostim** *A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects with Immune Thrombocytopenia (ITP)*, 2013, Clinical Trial.

P.I., Hemophilia Alliance Foundation 9765132, *Use of Massage Therapy in Patients with Hemophilia*. 2013— 6/30/2014. \$4,500

19. Clinical Service Contributions:

Authored supportive care guidelines for bleeding in children with Cancer for the Division of Pediatric Hematology/Oncology 2004.

Pediatric morning report three times per week 2000-2004 and weekly 2005-2007.

Pediatric Hematology Oncology Fellows text review weekly 2004-2007 and then yearly 2007-2013.

Camp WannaKlot Physician: Provide medical care to children with bleeding disorders during their summer camp experience. 2002-present, Medical director 2008-2013.

Camp Exchange Coordinator: Coordinate a summer camper exchange between the German Hemophilia Federation and Camp WannaKlot and Camp Eagle Outpost 2005-present.

Authored anesthesia guidelines for children with congenital bleeding disorders for the Division of Pediatric Hematology/Oncology 2008.

Co-Author and yearly reviewer Hemophilia of Georgia Nursing Guidelines 2004-2013.

Co-Author and yearly reviewed Hemophilia of Georgia Protocols for the Treatment of Hemophilia and Von Willebrand Disease 2004-2013.

CHOA Fellows FIRsT: Fellows Introduction to Research Training Panel, 2011-2013.

Aflac Blood Stream Infection Committee-2011-2013.

Author CHOA day surgery nursing educational guidelines for children with congenital bleeding disorders. 2012.

Representative to a meeting with Georgia State Medicaid regarding care of patients with bleeding disorders in the current managed care environment. May 29, 2012.

Aflac Epidemiology Faculty Recruitment Committee-2012-2013.

Aflac Quality Council-2013.

20. Formal Teaching:

a.	Medical Student Teaching:	Contact hours
	Pediatric Clerkship	5 hours/week 2000-2004
	Junior pediatric hem/onc clerkship	3 weeks/yr 2005-2013
	Clinical methods	1 hour/week 2000-2004
	Mentorship	2 hours/month 2011-2013
b.	Graduate Program	
	1. Residency Program	
	Pediatric wards	9 months/yr 2000-2004
	Pediatric Hem/Onc Ward	2 weeks/yr 2005-2013
	Pediatric Hem/Onc Consults	3 weeks/yr 2005-2013
	Pediatric Hem/Onc Clinic	1.5 days/week 2005-2013
	2. Physician Assistant Students	
	Pediatric Hem/Onc Electives	1 hour/month 2005-2013
	3. Hematology/Oncology Fellowship	
	Core competencies/text review	1 hour/week 2004-2007
		2 hours/yr 2007-2013
	Pediatric Hem/Onc ward	2 weeks/yr 2005-2013
	Pediatric Hem/Onc consults	3 weeks/yr 2005-2013
	Pediatric Hem/Onc clinic	1.5 days/week 2005-2013

21. Supervisory Teaching:
- a. Post-doctoral fellows directly supervised:
- | | | |
|------------------------|-----------|---|
| Shannon L. Meeks, M.D. | 2005-2008 | Assistant Professor of Pediatrics, Emory University |
|------------------------|-----------|---|
- b. Pediatric residents directly supervised:
- | | | |
|-----------------------|-----------|--|
| Alexia Gregory M.D. | 2000-2003 | Emory University - Private Practice Marietta, GA |
| Jennifer Nunn M.D. | 2001-2004 | Emory University-Private Practice Sandersville, GA |
| Rhada Nandagopal M.D. | 2003-2004 | Emory University- Assistant Professor of Pediatrics-Pediatric Endocrinology Children's National Medical Center Washington DC |
- c. Medical student directly supervised:
- | | | |
|-----------------------|-----------|-------------------|
| Catherine T. Crawford | 2010-2011 | Texas Tech SOM |
| Sarah E. McMullin | 2012-2013 | Saint Georges SOM |
- c. Undergraduate student directly supervised:
- Emory Physician Shadowing Program
- | | | |
|---------------------|-----------|--|
| Sarah E. McMullin | 2011-2012 | |
| Vijay Balarkrishnan | 2011-2012 | |
- The Hospital for Sick Children
- | | | |
|------------|---------------------------------------|--|
| Aubry Abad | Master's Thesis Review Committee 2014 | |
|------------|---------------------------------------|--|
22. Lectureships, Seminar Invitations, and Visiting Professorships:
1. Hemophilia Region IV South Annual meeting "Hemophilic Joint Disease" Fort Lauderdale, FL, March 1999.
 2. Hemophilia Region IV South Annual meeting "Hemophilic Joint Disease" Fort Lauderdale, FL, March 2000.

3. American Society of Pediatric Hematology/Oncology, "Hemophilic Arthropathy: A Critical Appraisal of Intervention Studies." Minneapolis, MN, September 14-16, 2000.
4. Georgia State Hemophilia Meeting "Joint Disease in Hemophilia" March 2000.
5. Georgia State Hemophilia Meeting "Joint Disease in Hemophilia" March 2001.
6. Emory University, "Prophylaxis for Hemophilia: Do the Data Support the Cost?" Hemophilia Nurse Coordinator Workshop, April 2001.
7. Emory University, "Prophylaxis for Hemophilia: Do the Data Support the Cost?" Hemophilia Nurse Coordinator Workshop, April 2002.
8. Emory University, "Prophylaxis for Hemophilia: Do the Data Support the Cost?" Hemophilia Nurse Coordinator Workshop, April 2003.
9. Trends in Comprehensive Hemophilia Care: Clinical Updates on FVIII Therapy and Evolving Roles in Patient Management" (sponsored by The American Red Cross), Boca Raton, FL, Feb 2003.
10. National Hemophilia Foundation Annual Meeting "Early Target Joint Intervention in Hemophilia", Salt Lake City, UT, November 2003.
11. American Society of Pediatric Hematology/Oncology, "Arthroscopic Synovectomy for Hemophilic Joint Disease" San Francisco, CA, April/May 2004.
12. Emory University, "Prophylaxis for Hemophilia: Do the Data Support the Cost?" Hemophilia Nurse Coordinator Workshop, April 2004.
13. The Hemophilia Joint: Under the Microscope "Synovectomy for Hemophilic Joint Disease" Toronto, Canada, November 2004.
14. National Hemophilia Foundation "Synovectomy for Hemophilic Joint disease" Dallas, TX, November 2004.
15. National Hemophilia Foundation "Management of Patients with Type 1 VWD Undergoing Adeno-tonsillar Procedures" Dallas, TX, November 2004.
16. Hemophilia Region IV South annual meeting "A Practical Approach to Target Joint Bleeding" Fort Lauderdale, FL, March 2005.
17. Emory University, "Prophylaxis for Hemophilia: Do the Data Support the Cost?" Hemophilia Nurse Coordinator Workshop, April 2005.

18. The Fourth Advances in Bleeding Disorders Meeting, Understanding Today Planning for Tomorrow "Hemophilic Joint Disease". New York, NY, February 2005.
19. Georgia State Hemophilia meeting "Radionuclide Synovectomy Update." March 2005.
20. Rockdale, Georgia Hospital pediatric morning conference "A Practical Approach to Anemia" April 2005.
21. American Society of Pediatric Hematology/Oncology "von Willebrand Disease (VWD): Challenges in Diagnosis and Treatment" Washington, DC, May 13, 2005.
22. National Hemophilia Foundation "Sports and Hemophilia A: Up for the Challenge." San Diego, CA, Oct 28, 2005.
23. National Hemophilia Foundation "Hot Topics in Bleeding Disorders." San Diego, CA, Oct 29, 2005.
24. National Hemophilia Foundation "Radionuclide Synovectomy: Safety and Efficacy." San Diego, CA, Oct 29, 2005.
25. Emory University, "Prophylaxis for Hemophilia: Do the Data Support the Cost?" Hemophilia Nurse Coordinator Workshop, March 2006.
26. State of Georgia Hemophilia Meeting, "Update on Clinical Trials" March 2006.
27. Hemophilia Region II Annual Meeting "What to do When Prophylaxis Fails" Fort Lauderdale, FL, September 2006.
28. World Federation of Hemophilia plenary session, "Management of Target Joints: Secondary Prophylaxis Versus Synovectomy" Vancouver, Canada, May 21-25, 2006.
29. Emory University, "Prophylaxis for Hemophilia: Do the Data Support the Cost?" Hemophilia Nurse Coordinator Workshop, April 2007.
30. American Society of Pediatric Hematology Oncology "Pathobiology of Blood Induced Joint Damage" Toronto, Canada May 4, 2007.
31. Emory University Coagulation Conference, "Diffuse Hemangiomatosis with Consumptive Coagulopathy" January 2007.
32. Emory University Coagulation Conference, "Medical Management of Menorrhagia" March 2007.
33. Emory University Coagulation Conference, "Leukemia and Hemophilia" May 2007.

34. Emory University Coagulation Conference, "Management of Recurrent Joint Bleeding in a Patient with Mild Hemophilia" October 2007.
35. Alliance of Five Meeting "Blood Induced Cartilage Changes in a Hemophilia A Murine Model" Dallas, TX October 4, 2007.
36. International Society of Thrombosis and Haemostasis, "Leukemia and Hemophilia" Geneva, Switzerland July 6-12, 2007.
37. International Society of Thrombosis and Haemostasis, "Management and Prevention of Recurrent Haemarthrosis in Haemophilia Patients: Advances and Emerging Challenges" Geneva, Switzerland, July 6-12, 2007.
38. Emory University, "Prophylaxis for Hemophilia: Do the Data Support the Cost?" Hemophilia Nurse Coordinator Workshop, April 2008.
39. State of Georgia Hemophilia Meeting, "Research Update" March 2008.
40. Mexican Annual National Hematology Meeting. "Prophylaxis in Hemophilia: Past, Present and Future" Laredo, Mexico July 2008.
41. Dalhousie University - Queen Elizabeth II Hospital, "Pathophysiology and Treatment of Hemophilic Joint Disease" Halifax, Canada September 4, 2008.
42. Dalhousie University - Izaak Walton Killam Hospital for Children. "How to Examine the Hemophilia Joint" Halifax, Canada, September 5, 2008.
43. Emory University Coagulation Conference, "Long Term Management of Stroke/TIA's in Pediatrics" February 2009.
44. Emory University Coagulation Conference, "Diagnosis and Management of Anti-phospholipid Antibody Syndrome" February 2009.
45. Emory University, "Prophylaxis for Hemophilia: Do the Data Support the Cost?" Hemophilia Nurse Coordinator Workshop, April 2009.
46. Emory University Coagulation Conference, "Hemoglobin SS and FVII deficiency" April 2010.
47. Emory University, "Prophylaxis for Hemophilia: Do the Data Support the Cost?" Hemophilia Nurse Coordinator Workshop, April 2010.
48. "Prophylaxis to Prevent Joint Disease" International Prophylaxis Study Group-Joint Pathobiology Expert Working Group, Los Angeles, CA September 12, 2010.
49. Emory University Coagulation Conference, "Challenging Patient Diagnoses". February 2011.

50. Emory University Coagulation Conference, "Factor XIII Combined with recombinant VIIa: a New Means of Treating Severe Hemophilia A" March 2011.
51. Emory University, "Prophylaxis for Hemophilia: Do the Data Support the Cost?" Hemophilia Nurse Coordinator Workshop, April 2011.
52. Emory University Hemostasis Journal Club-"Role of Factor XIII in Wound Healing in Hemophilia". March 2011.
53. CSL Behring Advisory Board, "rFVIIa – Overview of Published Study Results", Marburg, Germany, May 10, 2011.
54. International Pediatric Hemophilia Network "Medical Radiation Exposure in Children with Bleeding Disorders" Kyoto, Japan, July 2011.
55. Emory University Coagulation Conference: "Anticoagulation for Venous Stents". October 4, 2011.
56. Georgia State Hemophilia meeting: "A Patient with a Long-standing Inhibitor: Management and Laboratory Correlation". March 2, 2012.
57. Emory University Coagulation Conference with Lauren Taylor: "Thrombin Generation and Platelet Procoagulant Activity in Severe Hemophilia". April 3, 2012.
58. Hemophilia Region IV Annual meeting: "A Patient with a Long-standing inhibitor: Management and Laboratory Correlation". Hollywood, FL, May 21, 2012.
59. Hemophilia Region IV Annual Meeting: "A Complicated Case of Bernard-Soulier Syndrome-A Case for Bone Marrow Transplant". Hollywood, FL, May 21, 2012.
60. Emory/Aflac Research Conference: "Malignancy in Hemophilia-Is There a Connection". May 31, 2012.
61. International Pediatric Hemophilia Network: Central Venous Access Device Placement in Hemophilia Patients with Inhibitors". Paris, France July 7, 2012.
62. National Hemophilia Foundation-Inhibitor Summit. "Immune Tolerance Induction" Fort Lauderdale, FL, July 20, 2012.
63. National Hemophilia Foundation-Inhibitor Summit. "How, When & Why to Use Immunosuppressants" Fort Lauderdale, FL, July 20, 2012.
64. National Hemophilia Foundation-Inhibitor Summit. "Ask the Experts Rap Session" Fort Lauderdale, FL, July 21, 2012.

65. National Hemophilia Foundation Annual Meeting. Moderator "Addressing Therapeutic Gaps in Rare Bleeding Disorders", Orlando, FL, November 10, 2012.
66. Emory/Aflac Coagulation Conference: "Challenging Patient Presentations", December 4, 2012.
67. CSL Behring Von Willebrand Disease Regional Roundtable. Moderator, New York, NY, November 29, 2012.
68. CSL Behring Von Willebrand Disease Regional Roundtable. Moderator, Atlanta, GA, December 4, 2012.
69. Hemophilia Thrombosis Research Society Annual Meeting. "Clinical Conundrums" Expert panel participant. Charlotte, NC April 12, 2013.
70. Nationwide Children's Hospital Translational Research Conference. "Malignancy in Hemophilia-Is There a Connection". May 24, 2013.
71. International Society of Thrombosis and Haemostasis annual meeting. Amsterdam NL, June 28-July 4, 2013. Poster session 496; moderator.
72. Emory/Aflac Hem-Onc Division meeting: "3 Dimensional Gait Analysis in Hemophilia". September, 23, 2013.
73. Nationwide Children's Hospital Fellow lecture series: "Hemophilia 101", March 7, 2014.
74. Nationwide Children's Hospital Hemophilia Clinic Infusion Weekend: "Factor Products: Past, Present and Future". Deer Creek, Ohio March 8, 2014.
75. International Pediatric Hemophilia Network, "Predictors of the Hemophilia Phenotype" Melbourne, Australia May 9th, 2014.
76. CSL Behring Symposium-World Federation of Hemophilia "Progress on Recombinant Development", Melbourne, Australia May 11, 2014.
77. National Hemophilia Foundation-Inhibitor Summit. "Prophylaxis for Patients with Inhibitors" Baltimore, MD July 26, 2014.
78. National Hemophilia Foundation-Inhibitor Summit. "Meet the Experts-Rap Session" Baltimore, MD July 26, 2014.
79. Nationwide Children's Hospital Fellow lecture series: "Von Willebrand Disease", August 1, 2014.
80. FAMOHIO-Factor Products: Past, Present and Future, Dublin, Ohio August 9, 2014.

81. National Hemophilia Foundation Annual Meeting. "Treatment Options for Platelet Dysfunction" Washington DC, September 19, 2014.
 82. Great Lakes Regional Hemophilia Meeting "Quality Improvement" Grand Rapids Michigan, October 9, 2014.
 83. Selecting Optimal Outcome Measures for the Assessment of Hemophilic Arthropathy: An International Consensus Meeting. "Hemophilia Care: A Tale of Two Cities", Toronto, Canada, October 18, 2014.
 84. Mennonite Hemophilia Outreach Event, "Hemophilia 101" Plain City, Ohio, December 4, 2014.
 85. Central Ohio Hemophilia Chapter Education Days." Treatment Options for Platelet Dysfunction" Dublin, Ohio, December 8, 2014.
 86. "Hematologic Issues in the Newborn". Well baby nursery forum, Columbus, Ohio February 18, 2015.
 87. "Hemophilia update" Lounge and learn, Columbus, Ohio February 27, 2015.
 88. "Delivering Hemophilia Care in the Developed World "The 25st Annual Hemophilia Research Study Update, Berlin, Germany, March 13, 2015
 89. "Models for Orthopaedic Surgery Care for Patients with Hemophilia". Western States Hemophilia Treatment Centers annual conference, Los Angeles, CA. April 11, 2015.
 90. Use of Long-acting Factor VIII and IX-Implementation in Clinical Practice". Western States Hemophilia Treatment Centers annual conference, Los Angeles, CA. April 11, 2015.
 91. "Prophylaxis in Hemophilia B" CSL Behring Global Hemophilia Advisory Board, Marburg, Germany, April 23, 2015.
 92. "The Relationship between Factor VIII Product Choice and Inhibitors in PUPs: A Review of Recent Literature" Inhibitors to FVIII Translating the Bench to Bedside, Nationwide Children's Hospital Columbus, OH May 18, 2015.
23. Invitations to National or International Conferences:
1. "Radionuclide Synovectomy in Hemophilia (RASH) Working Group" meeting, Atlanta, GA. September 1998.
 2. Hemophilia Region IV South Annual meeting, Fort Lauderdale, FL, March 1999.
 3. Hemophilia Region IV South Annual meeting Fort Lauderdale, FL, March 2000.

4. American Society of Pediatric Hematology/Oncology, Minneapolis MN. September 2000.
5. Trends in Comprehensive Hemophilia Care: Clinical Updates on FVIII Therapy and Evolving Roles in Patient Management” (sponsored by The American Red Cross), Boca Raton, FL, February 2003,
6. National Hemophilia Foundation Annual Meeting, Salt Lake City, UT. November 2003.
7. American Society of Pediatric Hematology/Oncology, San Francisco CA. April/May 2004.
8. The Hemophilia Joint: Under the Microscope (sponsored by Novo Nordisk) Toronto, Ontario, November 2004.
9. National Hemophilia Foundation meeting, Dallas, TX November 2004.
10. The 15th Annual Hemophilia Research Study Update San Juan, PR, January 2005.
11. Hemophilia Region IV South Annual Meeting, Fort Lauderdale, FL, March 2005.
12. “Hemophilic Joint Disease” The Fourth Advances in Bleeding Disorders Meeting, Understanding Today Planning for Tomorrow. (sponsored by Bayer Corp) New York, NY, February 2005.
13. Von Willebrand Disease (VWD): Challenges in Diagnosis and Treatment (sponsored by ZLB Behring) American Society of Pediatric Hematology/Oncology, Washington DC, May 2005.
14. National Hemophilia Foundation, San Diego, CA October 2005.
15. Hemophilia Region II Annual Meeting, Albany, NY, April 2006.
16. The 16th Annual Hemophilia Research Study Update Lisbon, Portugal, April 2006.
17. World Federation of Hemophilia, Vancouver, Canada May 2006.
18. International Prophylaxis Study Group Biennial Meeting, Munich, Germany October 2006.
19. The 17th Annual Hemophilia Research Study Update. San Francisco, CA, March 2007.
20. International Prophylaxis Study Group Biennial Meeting, Toronto, Ontario October 2008.

21. CDC/UDC Stakeholders meeting, Atlanta, GA, December 2010.
22. Investigating the Biology of Blood Induced Joint Disease Los Angeles, CA, September 2010.
23. International Prophylaxis Study Group Biennial Meeting New York, NY, October 2010.
24. The 21st Annual Hemophilia Research Study Update Barcelona, Spain, March 2011.
25. International Pediatric Hemophilia Network, Kyoto, Japan July 2011.
26. Bleed Reduction in Prophylaxis Advisory Board, Atlanta, GA, February 2012.
27. Hemophilia Management Advisory Board, New Orleans, LA, March 2012.
28. Bayer Hemophilia Council, Dallas TX, March 2012.
29. CSL Behring Coagulation Advisory Board, Marburg, Germany April 2012.
30. National Hemophilia Foundation-Inhibitor Summit, Fort Lauderdale, FL, July 2012.
31. International Pediatric Hemophilia Network, Paris, France July 2012.
32. National Hemophilia Foundation Annual Meeting, Orlando, FL, November 2012.
33. Hemophilia Thrombosis Research Society Annual Meeting. Charlotte, NC April 11-13, 2013.
34. Pfizer Hemophilia Summit Advisory Board. Philadelphia PA, May 16-18, 2013.
35. Baxter PEG Advisory Board, Miami FL, January 23-24, 2014.
36. Baxter Considerations for Personalizing Treatment to Improve Patient Outcomes, Tampa FL, February 7-8, 2014.
37. The 24st Annual Hemophilia Research Study Update Washington DC, March 14-16, 2014
38. CSL Behring Global Advisory Board. Marburg Germany, March 20, 2014.
39. Bayer Hemophilia Advisory Board, Atlanta, GA, May 4-5, 2014.
40. International Pediatric Hemophilia Network-Melbourne, Australia, May 2014.
41. National Hemophilia Foundation Inhibitor Summit. Baltimore, MD, July 24-26, 2014.

42. National Hemophilia Foundation Annual Meeting. Washington DC, September 19, 2014.
 43. Selecting Optimal Outcome Measures for the Assessment of Hemophilic Arthropathy: An International Consensus Meeting. Toronto, Canada, October 17-18, 2014.
 44. International Prophylaxis Study Group Meeting New York, NY, November 2014.
 45. The 25st Annual Hemophilia Research Study Update Berlin Germany, March 12-14, 2015.
 46. Western States Hemophilia Treatment Centers Annual Conference, Los Angeles, CA, April 11-12, 2015.
 47. CSL Behring Global Advisory Board. Marburg Germany, May 22-23, 2015.
24. Bibliography:
- a. Published and accepted research articles in refereed journals:
 1. **Dunn AL**, Powers JR, Ribeiro MJ, Rickles FR, Abshire TC. (2000) "Adverse Events During use of Intranasal Desmopressin Acetate for Haemophilia A and von Willebrand Disease: a Case Report and Review of Forty Patients". *Haemophilia*; 6:611-614.
 2. **Dunn AL**, Busch MT, Abshire TC. (2002) "Radionuclide Synovectomy for Hemophilic Arthropathy: a Comprehensive Review of Safety and Efficacy and Recommendation for a Standardized Treatment Protocol". *Thrombos and Haemostas*; 87(3):383-393.
 3. **Dunn AL**, Busch MT, Wyly BJ, Sullivan KM, Abshire TC. (2004) "Arthroscopic Synovectomy for Hemophilic Joint Disease in a Pediatric Population". *J of Ped Orthop*; 24(4): 414-426.
 4. Giulino, Lisa B. MD; Bussel, James B. MD; Neufeld, Ellis J. MD, PhD; (2007) **Pediatric and Platelet Immunology Committees of the TMH Clinical Trial Network** "Treatment with Rituximab in Benign and Malignant Hematologic Disorders in Children". *J Pediatrics*; 150(4): 338-44.
 5. **Dunn AL**, Abshire TC. (2008) "Recombinant Tissue Plasminogen Activator may Reduce Frequency of Central Venous Access Device Infection in Hemophilia Patients Undergoing Immune Tolerance Therapy". *Ped Blood Cancer*; 50(3): 627-629.

6. **Dunn AL.** (2008) "Necrotizing Enterocolitis as a Result of Post-Circumcision Bleeding in a Neonate with Haemophilia A". *Haemophilia*, 14:1115–1116.
7. Doria AS, Lundin B, Miller S, Kilcoyne RF (in memoriam), Thomas S, **Dunn A**, Rivard GE, Babyn PS. (2008) "Reliability and Construct Validity of the Compatible MRI Scoring System for Evaluation of Haemophilic Elbows in Children". *Haemophilia*; 14(2): 303-314.
8. Miller W, **Dunn AL**, Chiang KY (2009) "Sustained Engraftment and Resolution of Bleeding Phenotype Following Unrelated Cord Blood Hematopoietic Stem Cell Transplantation for Severe Glanzmann Thrombasthenia". *J Ped Hematol Oncol*; 31(6): 436-439.
9. **Dunn AL.**, Cox Gill J. (2010) "Adenotonsillectomy in Patients with Desmopressin Responsive Mild Bleeding Disorders: A Review of the Literature." *Haemophilia*; 16(5): 711-716.
10. **Dunn AL.** (2010) "Malignancy in Patients with Hemophilia: A Review of the Literature" *Haemophilia*; 16(3): 427-436.
11. **Dunn AL** (2011) "Pathophysiology, Diagnosis, and Prevention of Arthropathy in Patients with Hemophilia" *Haemophilia*. 17(4): 571-578.
12. Hay CRM, DiMichelle DM. and the **ITI Study Group** (2012) "The Principle Results of the International Immune Tolerance Study: A Randomized Dose Comparison. *Blood* 119(6): 1335-44.
13. Miller CM and the **UDC Study Group** (2012) "Factor 8 and Factor 9 Mutations in U.S. Haemophilia Patients: Correlation with History of Inhibitor and Race/Ethnicity". *Haemophilia*- 18(3): 375-82.
14. **Dunn AL**, Austin H, Soucie JM (2012) "Prevalence of Malignancies Among U.S. Male Patients with Haemophilia: A Review of the Haemophilia Surveillance System". *Haemophilia*- 18(4): 532-9.
15. Miller CH, Platt SJ, Rice AS, Kelley F, Soucie JM and the **Hemophilia Inhibitor Research Study Investigators.** (2012) "Validation of Nijmegen–Bethesda Assay Modifications to Allow Inhibitor Measurement During Replacement Therapy and Facilitate Inhibitor Surveillance". *J of Thrombos and Haemostas* 10(6):1055–1061.
16. Ogawa S, Szlam F, Bolliger D, Ohnishi T, Hosokawa K, **Dunn A**, Tanaka K. (2012) "Evaluation of a Novel Flow Chamber System to Assess Clot Formation in Factor VIII-Deficient Mouse and Anti-factor IXa-treated Human Blood". *Haemophilia* 18(6):926-32.
17. **Dunn, A**, Meeks, S, Crawford, C. (2012) "Medical Radiation Exposure in Children with Bleeding Disorders: An Institutional Experience". *Haemophilia*18 (6):888-891.

18. Lundin, B, Manco-Johnson, M; Ignas, D, Moineddin, R, Blanchette, V, **Dunn, A**; Gibikote, S; Keshava, S; Ljung, R, Manco-Johnson, M. (2012) "An MRI Scale for Assessment of Haemophilic Arthropathy from the International Prophylaxis Study Group". *Haemophilia-8* (6): 962-970.
19. Balakrishnan, V. **Dunn, AL**. (2012) "A Case of Pigmented Villonodular Synovitis in Conjunction with a Platelet Release Defect in a Pediatric Patient". *Haemophilia-Mar*;19(2):e89-90.
20. Meeks, SL, Chapman R, Kempton CL, **Dunn AL**. (2012) "Late Immune Tolerance Induction in Haemophilia A Patients. *Haemophilia-May*;19(3):445-8.
21. Flood VH, Friedman K, Gill J, Haberichter S, Christopherson P, Branchford B, Hoffman R, Abshire T, **Dunn A**, Di Paola J, Hoots W, Brown D, Leissing C, Lusher J, Ragni M, Shapiro A, Montgomery R. (2013) "No Increase in Bleeding Identified in Type 1 VWD Subjects With D1472H Sequence Variation". *Blood* (121); 3742-3744.
22. Miller CM, Rice AS, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, Kelly FM, Soucie JM, and **the Hemophilia Inhibitor Research Study Investigators** (2013). "Comparison of Clot-based, Chromogenic, and Fluorescence Assays for Measurement of Factor VIII Inhibitors in the U.S. Hemophilia Inhibitor Research Study" *J Throm Haemostas* (11): 1300-1309.
23. Boylan B, Anne S. Rice AS, **Dunn AL**, Tarantino M, Brettler DB, Barrett JC, Miller CH, and the Hemophilia Inhibitor Research Study Investigators (2015). Characterization of the Anti-Factor VIII Immunoglobulin Profile in Patients With Hemophilia A Using a Fluorescence-Based Immunoassay. *J Throm Haemostas-13*(1):47-53.
24. Boylan B, Rice AS, De Staercke C, Eyster EM, Yaish HM, Knoll CM, Bean CJ, Miller CH, and the **Hemophilia Inhibitor Research Study Investigators*** (2015) Evaluation of VWF phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations. *J Throm Haemostas*-in press
25. Ljung R, Fischer K, Carcao M, Satagostino E, Mando-Johnson M, Mathew P and the **INPH group of investigators (2015)**. How do I choose a prophylactic regimen in patients with severe hemophilia A: role of clinical phenotype and trough levels-submitted

b. Book Chapters, Invited Reviews, Reviews, Non-peer Reviewed Articles and Editorial Articles

1. **Dunn AL.** (2002) First and second generation recombinant factor eight products: Aventis Behring Foundation Newsletter Summer.
2. **Dunn AL.** (2003) Future therapy for hemophilia A: Aventis Behring Foundation Newsletter Winter.
3. **Dunn AL.** (2003) Inhibitors: a patients and healthcare professionals challenge: Aventis Behring Foundation Newsletter; 3(1).
4. **Dunn AL.** (2003) Prophylactic treatment options for people with severe hemophilia a: Aventis Behring Foundation Newsletter; 3(2).
5. **Dunn AL.** (2005) Management and prevention of recurrent hemarthrosis in patients with hemophilia. *Current Opinion in Hematology*; 12(5): 390-394.
6. **Dunn AL,** Abshire TC. (2005) Recent Advances in the Care of the Child with Hemophilia. *Hematology/Oncology Clinics of North America* Special issue: Non-Malignant Disorders of the Blood in Infants and Children - Edited by G.R. Buchanan; 18(6): 1249-1276.
7. **Dunn AL,** Manco-Johnson M, Busch MT, Balark K, Abshire TC. (2005) Leukemia after P32 Radionuclide Synovectomy for Hemophilic Arthropathy. *Journal of Thrombosis and Haemostasis* 3 (7):1541.
8. **Dunn AL,** Abshire TC. (2006) Current Issues in Prophylactic Therapy for Persons with Hemophilia. edited by Kenet G for a special edition of pediatric coagulation in *Acta Haematologica* 115(3-4):162-171.
9. Van den Berg HM, **Dunn AL,** Fischer K, Blanchette VS. (2006) Prevention and Treatment of Musculoskeletal Disease in the Haemophilia Population: Role of Prophylaxis and Synovectomy. *Haemophilia*; 12(s3): 159-168.
10. **Dunn AL,** Meeks SL, Abshire TC. (2010) Hemophilia and Other Inherited Bleeding Disorders. *Rudolph's Textbook of Pediatrics* 22nd Edition. Colin Rudolph, Lewis First, Anne Gershon, George Lister, Abraham Rudolph, and Joe Zenel Editors McGraw-Hill. Chapter 436.
11. **Dunn AL.** (2009) Disseminated Intravascular Coagulopathy. In: *Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects*. Editors: Christopher D. Hillyer, Beth H. Shaz, James C. Zimring, and Thomas C. Abshire. Elsevier. Chapter 110, 589-594.
12. **Dunn AL.** (2009) Hemophilia A. In: *Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects*. Editors: Christopher D. Hillyer, Beth H. Shaz, James C. Zimring, and Thomas C. Abshire. Elsevier. Chapter 96, 527-532.

13. **Dunn AL.** (2009) Hemophilia B. In: Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. Editors: Christopher D. Hillyer, Beth H. Shaz, James C. Zimring, and Thomas C. Abshire. Elsevier. Chapter 97, 533-536.
14. **Dunn AL.** (2009) Factor VIII Concentrates. In: Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. Editors: Christopher D. Hillyer, Beth H. Shaz, James C. Zimring, and Thomas C. Abshire. Elsevier. Chapter 145, 729-734.
15. **Dunn AL.** (2009) Factor IX Products. In: Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. Editors: Christopher D. Hillyer, Beth H. Shaz, James C. Zimring, and Thomas C. Abshire. Elsevier. Chapter 146, 735-738.
16. **Dunn AL.** (2013) Hemophilia A. In: Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. Editors: Beth H. Shaz, Christopher D. Hillyer, Mikhail Roshal, and Charles S. Abrams. Elsevier—Chapter 106, 699-704.
17. **Dunn AL.** (2013) Hemophilia B. In: Transfusion medicine and Hemostasis: Clinical and Laboratory Aspects. Editors: Beth H. Shaz, Christopher D. Hillyer, Mikhail Roshal, and Charles S. Abrams. Elsevier –Chapter 107, 705-710.
18. **Dunn AL.** (2013) Disseminated Intravascular Coagulopathy. In: Transfusion medicine and Hemostasis: Clinical and Laboratory Aspects. Editors: Beth H. Shaz, Christopher D. Hillyer, Mikhail Roshal, and Charles S. Abrams. Elsevier.—Chapter 120, 775-780.
19. Busch M, **Dunn AL.** (2014) Diseases of the Hematopoietic System in Lovell and Winters Pediatric Orthopedics-7th Edition Editors Raymond T. Morrissy and Stuart L. Weinstein, Chapter 10.
20. **Dunn AL.** (2014) Hemophilia and Family Vacations Nationwide Children's Hospital Blog. March 28, 2014.
21. Woods, G and **Dunn, A.** (2015) Coagulation Concentrates for Inherited Bleeding Disorders. In: Simon, T., McCullough, J., Snyder, E., et. al. eds. Rossi's Principles of Transfusion Medicine. 5th ed. West Sussex, UK: Wiley-Blackwell, in press.

c. Abstracts Published/Presented:

1. **Dunn AL,** Busch MT, Wyly JB, Abshire TC. (1999) Arthroscopic Synovectomy Reduces Joint Bleeding in Pediatric Hemophilia Patients: a Long-term Follow-up Study. Featured poster at the International Society of Thrombosis and Haemostasis, August 14-21. Washington DC.

2. **Dunn AL**, Busch MT, Wylly JB, Abshire TC. (1999). Arthroscopic Synovectomy Reduces Joint Bleeding in Pediatric Hemophilia Patients: a Long-term Follow-up Study. National Hemophilia Foundation, November 4-6. Dallas, Texas.
3. **Dunn AL**, Busch MT, Wylly JB, Abshire TC. (2002) Arthroscopic Synovectomy Reduces Joint Bleeding in Pediatric Hemophilia Patients. World Federation of Haemophilia, May 19-24. Seville, Spain.
4. **Dunn AL**, Manco-Johnson M, Busch MT, Balark K, Abshire TC. (2005) Leukemia and P32 Radionuclide Synovectomy for Hemophilic Arthropathy. International Society of Thrombosis and Haemostasis, August 8-12. Sydney Australia.
5. Doria AS, Lundin B, Miller S F, Thomas S, **Dunn AL**; Babyn P S. (2007) Measurement Properties of the Compatible MRI Scoring System for Evaluation of Hemophilic Elbows in Children Radiologic Society of North America, November 25-30, Chicago Illinois.
6. **Dunn AL**, Shehata BM. (2007) Blood Induced Cartilage Changes in a Hemophilia A Murine Model. American Society of Hematology, Atlanta Georgia. November 110: 1152.
7. Lundin B, Doria A, **Dunn A**, Gibikote S, Keshava S, Ljung R, Manco-Johnson ML, Rivard G, and Babyn P on behalf of the Expert Imaging Committee of the International Prophylaxis Study Group A. (2008) Basic Scale For Magnetic Resonance Imaging Assessment of Haemophilic Arthropathy, World Federation of Haemophilia, Istanbul Turkey.
8. Chapman RL, Meeks SL, **Dunn AL**. (2008) Characterization of Immune Tolerance in Patients with Hemophilia A and Long-standing Inhibitors. National Hemophilia Foundation, Denver Colorado. November 2008.
9. Miller CH, Hooper C, Abshire TC, Bockenstedt PL, Brettler DB, Di Paola J, Massey G, Neff AT, Shapiro AD, Tarantino M, Wicklund BM, Manco-Johnson MJ, **Dunn AL**, Knoll C, Creary M, Benson J, Ellingsen D, Driggers J and Soucie JM. (2008) Factor VIII and Factor IX Mutation Analysis in 600 U.S. Hemophilia Patients: Correlation of Mutation Type with History of Inhibitor. American Society of Hematology, San Francisco, California. December 2008.
10. **Dunn AL**, Meeks SL, Chapman RL, Kempton CL. (2009) Immune Tolerance in Patients with Hemophilia A and Longstanding Inhibitors. International Society of Thrombosis and Hemostasis, July 10-16.
11. Soucie JM, Creary M, Abshire TC, Bockenstedt PL, Brettler DB, Di Paola J, Massey G, Neff AT, Shapiro AD, Tarantino M, Wicklund BM,

- Manco-Johnson MJ, **Dunn AL**, Knoll C, Driggers J, Benson J, Ellingsen D, Hooper C, and Miller CH. (2009) Inhibitor Surveillance and Mutation Analysis in Hemophilia B Patients. International Society of Thrombosis and Hemostasis, July 10-16. Geneva, Switzerland.
12. Miller CH, Hooper C, Benson J, Ellingsen D, Driggers J, Abshire TC, Bockenstedt PL, Brettler DB, Di Paola J, Massey G, Neff AT, Shapiro AD, Tarantino M, Wicklund BM, Manco-Johnson MJ, **Dunn AL**, Knoll C, Creary M, Soucie JM. (2009) Novel Factor VIII Mutations in US Hemophilia Patients: Relationship to Ethnicity and Inhibitor History - International Society of Thrombosis and Hemostasis, July 10-16. Geneva, Switzerland.
 13. Meeks SL, Parker ET, **Dunn AL**, Healey JF, Lollar JS. (2009) Proteolytically Inactivatable Factor VIII is less Immunogenic than Factor VIII in a Murine Hemophilia A Model. American Society of Hematology, December, 2009. Atlanta, GA.
 14. Lundin B, Ignas DM, Moineddin R, Miller S, Manco-Johnson M, Ljung R, **Dunn AL**, Rivard GE, Babyn P, Keshava S, Gibikote S, Blanchette VS, Doria AS. A Basic MRI scale for Hemophilic Arthropathy from the International Prophylaxis Study Group-International Society of Thrombosis and Hemostasis, July 23-28, 2011 Kyoto, Japan.
 15. Crawford, CC, Meeks SL, **Dunn AL**. Medical Radiation in Children with Bleeding Disorders. Hemophilia and Thrombosis Research Society. April 28-29, 2011- awarded the travel award, Chicago, IL
 16. Chapman R, Cox C, **Dunn A**, Meeks, S. Changes in Epitope Specificity, Inhibitor Titer, and Antibody Tier in a Patient with Severe Hemophilia A Undergoing Immune Tolerance Therapy with Rituximab and Recombinant Factor VIII. Thrombosis and Hemostasis Summit of North America, May 4, 2012. Chicago, IL.
 17. Batsuli G, Chapman R, Cox C, **Dunn A**, Meeks, S. Role of Race and Ethnicity on Immune Tolerance Induction and Inhibitor Relapse in Children with Hemophilia A. American Society of Pediatric Hematology/Oncology, May 9-12, 2012, New Orleans, LA
 18. Taylor LY **Dunn AL**, Niesler JB, Zhou CZ, Szlam F, Tanaka KA, and Jobe SM. Thrombin Generation and Platelet Procoagulant Activity in Severe Hemophilia. American Society of Pediatric Hematology/Oncology, May 9-12, 2012, New Orleans, LA.
 19. **Dunn AL**, Taylor LY, Niesler JB, Zhou CZ, Szlam F, Tanaka KA, and Jobe SM. Thrombin Generation and Platelet Procoagulant Activity in Severe Hemophilia. World Federation of Haemophilia, June 8-12, 2012, Paris, France.

20. **Dunn AL**, Chapman RL, Meeks, SL. One Year Follow-up of Changes in Epitope Specificity, Inhibitor Titer, and Antibody Titer in a Patient with Severe Hemophilia A after Rituximab. Hemophilia and Thrombosis Research Society. April 11-12, 2013, Charlotte, NC.
21. Taylor LF, Jobe SM, **Dunn AD**. History of Intracranial Hemorrhage or Joint Surgery In Patients With Severe Hemophilia Correlates With A Higher Hemophilia Severity Score”, Hemophilia and Thrombosis Research Society. April 11-12, 2013, Charlotte, NC.
22. **Dunn AD**, Taylor LF, Jobe SM. Factor VIII Genotype and Correlation with the Hemophilia Severity Score. International Society of Thrombosis and Hemostasis. June 29-July 4, 2013. Amsterdam NL.
23. Long-term Orthopedic Effects of Delaying Prophylaxis in Severe Hemophilia A Until Age 6 years: Interim Results of the Joint Outcome Study Continuation Project. Manco-Johnson MJ , Manco-Johnson ML, Blades TA, Funk S, Lane H, McRedmond KP, **Dunn A** , Recht M, Shapiro AD, Valentino LA, Brown D Kittelson J. American Society of Hematology, December 2013 New Orleans, LA.
24. Livnat T, **Dunn AL** , Azar-Avivi S, Baldwin WH, G. Kenet G, Meeks SL. Epitope Specific Discrepancies between Antibody Mediated Inhibition of Recombinant Factor VIII and Plasma Derived Factor VIII Containing von Willebrand Factor Affecting All Domains of Factor VIII. American Society of Hematology, December 2013, New Orleans, LA.
25. **Dunn AD**, Leong T, Hellwege D, Nguyen B, Jobe SM. The Influence of Race and Ethnicity on the Hemophilia Phenotype. Thrombosis and Hemostasis Summit of North America. April 2014, Chicago IL.
26. **Dunn AL**, Nguyen B, Baldwin WH, Kenet G, Meeks SL. Predictors of Response to Combination Therapy with Recombinant Factor VIIa and Factor VIII in Patients with Hemophilia A and High Titer Inhibitors World Federation of Hemophilia May 2014, Melbourne Australia.
27. Manco-Johnson MJ, Manco-Johnson ML, Blades TA, Funk S, Lane H, McRedmond K, **Dunn AL**, Recht M, Shapiro AD, Valentino LA and Brown D, What is the cost of delaying prophylaxis until the school years? Results from the Joint Outcome Study Continuation Project. World Federation of Hemophilia May 2014 Melbourne Australia.
28. G Hilliard P, Abad A, Feldman BM, Funk S, Manco-Johnson M, Petrini P, van der Net J, Zourikian N, and Blanchette VS on behalf of **The International Prophylaxis Study Group** Global utilization of the International Prophylaxis Study Group (IPSG) Physical Therapy Hemophilia Joint Health Score (HJHS) Education Web-site Module. World Federation of Hemophilia May 2014, Melbourne Australia.

29. Meeks S, Koval B, Kennedy C, **Dunn A**. The Use of Combination Therapy with Plasma Derived and Recombinant Factor VIII in Patients with Hemophilia A: A Single Institution Experience" National Hemophilia Foundation. September 2014, Washington, DC.
30. Xi M, Navarro-Ruan T, Mammen S, Blanchette V, Hermans C, Morfini M, Collins P, Fischer K, Neufeld E. J, Young G, Kavakli K, Radossi P, **Dunn A**, Thabane L, Iorio A for the WAPPS study group. Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates. American Society of Hemophilia Annual Meeting. December, 2014, San Francisco, CA.
31. Livnat T, **Dunn A**, Azar-Avivi S, Cox, C, Avishai E, Meeks S, Kenet G. Beyond the Bethesda Assay- Towards Individualized Interpretation of Inhibitor Patients' Profiles. American Society of Hemophilia Annual Meeting. December, 2014, San Francisco, CA.
32. Iorio A, Blanchette V, Blatny J, Collins JP, Croteau S, **Dunn A**, Fischer K, Hermans C, Kavakli K, Jackson S, James P, Mammen S, Morfini M, Navarro-Ruan T, Neufeld EJ, Ozelo M, Radossi P, Rangarajan S, Ruiz-Sàez A, Teitel J, Thabane L, Young G, Xi M. A Population Approach To Hemophilia Pharmacokinetics. Wapps: A Web-Service For Bayesian Post Hoc Estimation International Society of Thrombosis and Hemostasis Annual Meeting, June 2015, Toronto, Canada.
33. Xi M, Blanchette V, Blatny J, Collins JP, **Dunn A**, Fischer K, Hermans C, Navarro-Ruan T, Kavakli K, Jackson S, James P, Mammen S, Morfini M, Neufeld EJ, Ozelo M, Radossi P, Rangarajan S, Ruiz-Sàez A, Teitel J, Thabane L, Young G, Iorio A. on behalf of the WAPPS investigators. Pharmacokinetic Characteristics Of Factor VIII And IX Concentrates – International Society of Thrombosis and Hemostasis Annual Meeting, June 2015, Toronto, Canada.
34. Woods G, Harrison S, Texter K, Stanek J, **Dunn A**, Kerlin B, Kumar R. Correlation Between Activated Partial Thromboplastin Time (APTT) And Anti-Fxa Assay In Children On Unfractionated Heparin (UFH) Therapy: An Institutional Experience. International Society of Thrombosis and Hemostasis Annual Meeting, June 2015, Toronto, Canada.
35. Woods G, Sharma R, **Dunn A**, Creary S, Hor K, Young J, Young C, Kumar R. Venous Thrombo-Embolism (VTE) In Children with Sickle Cell Disease (SCD): An Institutional Experience International Society of Thrombosis and Hemostasis Annual Meeting, June 2015, Toronto, Canada.